Can Charles River Laboratories International (CRL) Justify Its Valuation On Its Rapid Cell Banking Launch?

Charles River Laboratories International (CRL) just rolled out rapid cell banking programs built around Next-Generation Sequencing and its Pathoquest acquisition, aiming to shorten development timelines for advanced therapies and strengthen quality and regulatory control. For context, Charles River Laboratories International has seen strong momentum build over the past few months, with a 90-day share price return of 52.25% and a 1-year total shareholder return of 79.42%. These figures point...